Translate page

iStock 1203771991 CoronavirusIn this ever changing COVID-19 (coronavirus) pandememic keeping up to date with reliable information is key. In an effort to serve the CML community best during these difficult times, we have created this COVID-19 hub to provide you with expert statements, frequenty asked questions, relevant clinical papers and other reliable ressources.

We will be keeping you updated as more information becomes available.

If you have specific questions or want to share information around COVID-19 and CML that has been particularly helpful to you, please email

To answer key questions on the impact of COVID-19 for patients with CML and to help physicians confidently treat people with CML during the pandemic, the iCMLf has collected and analysed COVID-19 cases among patients with CML globally.

The full case summary comprises a total case number of 1,056 COVID-19 and CML cases submitted from 177 institutions in 57 countries and 205 physicians, and represents the largest global cohort of CML patients with COVID-19.

'The iCMLf CANDID study gave confidence for physicians worldwide that their patients with well controlled CML were not at greater risk from COVID-19 than the general population and no changes to CML therapy specifically due to SARS-CoV-2 infection were required.’ (Professor Jorge Cortes)

Below we summarise the key data that have been presented at major meetings from this important registry.

The iCMLf has compiled for you expert talks, frequently asked questions, statements, expert opinions and interesting cases on COVID-19 and CML from reliable sources.

On this section you will find statements, expert talks and frequently asked questions about COVID-19 vaccines and CML.

The iCMLf is sharing a selection of interesting scientific publications on COVID-19 and CML from peer-reviewed journals.